Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Watson Pharmaceuticals Receives A Complete Response Letter For Its 24-Week Formulation Of TRELSTAR(R) (triptorelin Pamoate) NDA From US FDA
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for TRELSTAR(R) 22.5 mg (triptorelin pamoate for injectable suspension), a 24-week formulation of TRELSTAR(R) for the palliative treatment of advanced prostate cancer. The TRELSTAR(R) NDA was prepared in cooperation with Debiopharm Group, a Swiss-based global biopharmaceutical group of companies.
generic viagra online
Selenium Intake May Worsen Prostate Cancer In Some
Higher selenium levels in the blood may worsen prostate cancer in some men who already have the disease, according to a study by researchers at Dana-Farber Cancer Institute and the University of California, San Francisco.
News of the day
Intervention Program Targets Siblings
"Siblings are Special," a pilot prevention program targeting fifth graders and their younger siblings, recently received $1.45 million from the National Institute on Drug Abuse as part of the National Institutes of Health"s American Recovery and Reinvestment Act funding. The award is for two years.
Health Insurance

British Medical Journal Report Supports SCHS White Paper On Statins

The results of a study published in the current issue of the peer reviewed British Medical Journal (BMJ) support the findings of a white paper released last month by the Senior Center for Health and Security (SCHS) regarding the potentially lifesaving qualities of cholesterol lowering drugs known as statins. The report concluded, "In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events." A meta-analysis of 10 significant statin trials involving more than 70,000 patients published in the June 30 BMJ show that statins can reduce the risk of death by 12%, reduce coronary events by 30% and cardiovascular events by 19%. Researchers also underscored the potential value of statins to men 65 years of age and older and older women with diabetes and other cardiovascular risk factors noting that, "it is likely that a considerable number of such people would benefit from long-term statin use," wrote the study"s authors, led by Dr. Jasper Brugts of the Erasmus MC Thoraxcenter in Rotterdam, the Netherlands. The BMJ findings parallel those of the June 29 white paper by the SCHS which found that research indicates statin use can not only help patients lower their cholesterol but can have other life saving benefits as well. "More Americans and growing portions of the global medical community are coming to an important consensus on the potential of statins to improve heart health and save lives," said SCHS Policy Director Al Cors. "We"ve been educating seniors on this issue for years and we"re seeing more data and research supporting those efforts. Cors noted the importance of recognizing the many types of statins and how each may play a role in addressing the specific cardiovascular risks for each patient. "Only by talking with their doctor can patients make sure they receive the right statin to meet their cholesterol goals through a well monitored regimen," said Cors. Senior Center for Health and Security


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009